Journal
INTERNATIONAL JOURNAL OF HYPERTHERMIA
Volume 38, Issue 1, Pages 732-742Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02656736.2021.1916100
Keywords
Renal denervation; hypertension; chronic kidney disease; end-stage renal disease; meta-analysis
Funding
- Sichuan Traditional Chinese Medicine Research Program [2020LC0146]
Ask authors/readers for more resources
This meta-analysis included 238 patients from 11 single-center, non-randomized, uncontrolled studies. The results showed that RDN may be effective and safe for treating CKD patients with hypertension, with significant reductions in blood pressure and urinary albumin-to-creatinine ratio observed after the procedure. Further well-designed randomized controlled trials are needed to confirm these findings and assess the impact on clinical outcomes.
Background Renal denervation (RDN) is a new treatment for hypertension in patients with chronic kidney disease (CKD), but its efficacy is still debated. This meta-analysis aimed to evaluate the efficacy and safety of RDN for hypertension in patients with CKD. Methods PubMed, Web of Science, EMBASE, and Ovid databases were searched for relevant studies published. We performed both fixed- and random-effects meta-analyses of the changes in blood pressure, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR) after RDN. Results The meta-analysis included 238 patients from 11 single-center, non-randomized, uncontrolled studies. Office blood pressure and 24-hour ambulatory blood pressure (24 h-ABP) showed a significant reduction 1 month after RDN (p < 0.05). This decrease of 24 h-ABP persisted for 24 months after RDN showed difference systolic blood pressure (p < 0.001) and diastolic blood pressure (p = 0.001). The 24 h-ABP exhibited a similar trend in the subgroup analysis. eGFR measurements obtained at each time point of analysis after RDN were not significantly different from those obtained before (p > 0.05). UACR levels were significantly reduced at 3 months and 6 months after RDN (p < 0.001). After RDN, the heart rate showed no significant changes (p > 0.05), and few major complications were encountered. Conclusions The meta-analysis showed that RDN may be effective and safe for treating CKD patients with hypertension. Well-designed randomized controlled trials of RDN are urgently needed to confirm the safety and reproducibility of RDN and to assess its impact on clinical outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available